LeonaBio

LeonaBio Stock-Based Compensation

The Stock-Based Compensation (SBC) of LeonaBio (LONA) as of Nov 6, 2026 is 6.10 M USD. In the previous year, Stock-Based Compensation (SBC) was 11.05 M USD — a change of -44.77% (lower).

Stock-Based Compensation

6.10 MUSD

YoY

-44.77%

Last updated:

Stock-Based Compensation (SBC) of LeonaBio is 2025 6.10 M USD. Stock-Based Compensation (SBC) of LeonaBio was 2024 11.05 M USD. It decreases by -44.77% lower compared to the previous year.

The LeonaBio Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
196,000.00 USD
Jan 1, 2019
253,000.00 USD
Jan 1, 2020
633,000.00 USD
Jan 1, 2021
4.62 M USD
Jan 1, 2022
10.61 M USD
Jan 1, 2023
10.62 M USD
Jan 1, 2024
11.05 M USD
Jan 1, 2025
6.10 M USD
The LeonaBio Stock-Based Compensation history
YEARStock-Based CompensationYoY
6.10 MUSD-44.77%
11.05 MUSD+4.01%
10.62 MUSD+0.16%
10.61 MUSD+129.42%
4.62 MUSD+630.33%
633,000.00USD+150.20%
253,000.00USD+29.08%
196,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

Stock-Based Compensation (SBC) of LeonaBio is 6.10 M USD in 2025.

Stock-Based Compensation (SBC) of LeonaBio changed from 11.05 M USD to 6.10 M USD, representing a -44.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) LeonaBio since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s LeonaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — LeonaBio

All Key Metrics — LeonaBio